SCHEMBL4424326

SCHEMBL4424326

CNc1ncc2cc(-c3cc(N)ccc3Cl)c(=O)n(C)c2n1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 6/20 0.67
SRC P12931 5/20 0.67
EGFR P00533 4/20 0.67
ABL1 P00519 4/20 0.60
PDGFRB P09619 2/20 0.59
PDGFRA P16234 2/20 0.59
MAPK14 Q16539 2/20 0.59
KIT P10721 1/20 0.59
SIK2 Q9H0K1 5/20 0.58
SIK1 P57059 4/20 0.58
SIK3 Q9Y2K2 4/20 0.58
STK4 Q13043 1/20 0.57
STK3 Q13188 1/20 0.57
STK26 Q9P289 1/20 0.57
STK24 Q9Y6E0 1/20 0.57
WEE1 P30291 4/20 0.56
PAK1 Q13153 1/20 0.55
RIPK2 O43353 1/20 0.52
NOD2 Q9HC29 1/20 0.52
FGFR2 P21802 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30078208 1.00 FGFR1 (0.67) FGFR1SRCEGFRABL1PDGFRB
SCHEMBL24885903 0.87 SRC (0.58) FGFR1SRCEGFRABL1PDGFRB
SCHEMBL30078171 0.87 SRC (0.58) FGFR1SRCEGFRABL1PDGFRB
SCHEMBL30078142 0.82 WEE1 (0.76) FGFR1SRCEGFRABL1PDGFRB
SCHEMBL24885870 0.82 WEE1 (0.76) FGFR1SRCEGFRABL1PDGFRB
SCHEMBL30078284 0.82 WEE1 (0.59) FGFR1SRCEGFRABL1PDGFRB
SCHEMBL24885871 0.82 WEE1 (0.59) FGFR1SRCEGFRABL1PDGFRB
SCHEMBL4420167 0.82 FGFR1 (0.51) FGFR1SRCEGFRABL1PDGFRB
SCHEMBL5061792 0.81 ABL1 (0.67) FGFR1SRCEGFRABL1PDGFRB
SCHEMBL5762058 0.80 FGFR1 (1.00) FGFR1SRCEGFRABL1PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400577-A1 MODULATORS OF PROTEIN KINASES VIBLIOME THERAPEUTICS, LLC 2024-12-05 US disclosed
WO-2023283369-A1 MODULATORS OF PROTEIN KINASES VIBLIOME THERAPEUTICS, LLC (US) 2023-01-12 WO disclosed
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2012-11-15 US disclosed
US-8188113-B2 For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies DECIPHERA PHARMACEUTICALS, INC. (US) 2012-05-29 US disclosed
EP-2063897-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP disclosed
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PARMACEUTICALS, LLC (US) 2008-05-15 US disclosed
WO-2008034008-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC. (US) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400577-A1 MODULATORS OF PROTEIN KINASES MAP3K20, PRKCE, PRKCH FGFR1 1581/4885SRC 121/4885EGFR 862/4885
US-20120289540-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES BRAF, PRKDC, RAF1 FGFR1 577/4885SRC 417/4885EGFR 349/4885
US-20080114006-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 FGFR1 577/4885SRC 417/4885EGFR 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.